Multimarker risk stratification approach at multiple sclerosis onset

Multimarker risk stratification approach at multiple sclerosis onset

Copyright © 2017 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 181(2017) vom: 01. Aug., Seite 43-50
1. Verfasser: Fernández-Paredes, Lidia (VerfasserIn)
Weitere Verfasser: Casrouge, Armanda, Decalf, Jérémie, de Andrés, Clara, Villar, Luisa Maria, Pérez de Diego, Rebeca, Alonso, Bárbara, Álvarez Cermeño, José Carlos, Arroyo, Rafael, Tejera-Alhambra, Marta, Navarro, Joaquín, Oreja-Guevara, Celia, López Trascasa, Margarita, Seyfferth, Ansgar, García Martínez, Maria Angel, Álvarez Lafuente, Roberto, Albert, Matthew L, Sánchez-Ramón, Silvia
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Biomarkers Diagnostic Innate immunity deregulation Prognostic CCL11 protein, human CCL2 protein, human CCL4 protein, human CCL5 protein, human mehr... CXCL10 protein, human CXCL9 protein, human Chemokine CCL11 Chemokine CCL2 Chemokine CCL4 Chemokine CCL5 Chemokine CXCL10 Chemokine CXCL9 HGF protein, human IL1RN protein, human IL7 protein, human Interleukin 1 Receptor Antagonist Protein Interleukin-7 Fibroblast Growth Factor 2 103107-01-3 Epidermal Growth Factor 62229-50-9 Hepatocyte Growth Factor 67256-21-7 DPP4 protein, human EC 3.4.14.5 Dipeptidyl Peptidase 4
Beschreibung
Zusammenfassung:Copyright © 2017 Elsevier Inc. All rights reserved.
Delay in the diagnosis of multiple sclerosis (MS) stems from the lack of specific clinical and analytical markers to assist in the early diagnosis and prediction of progressive course. We propose a decision-tree model that better defines early at onset MS patients and those with the progressive form by analysing a 12-biomarkers panel in serum and CSF samples of patients with MS, other neurological diseases (OND) and healthy contols. Thus, patients at onset of neurological disease were first classified by serum IL-7 levels <141pg/ml (OR=6.51, p<0.001). Combination of IL-7 and CXCL10 indicated risk for a specific MS clinical form, where IL-7<141 and CXCL10<570pg/ml were associated with the highest risk for PP-MS (OR=22, p=0.01). Unexpectedly, both PP-MS and RR-MS patients shared significantly decreased prototypical biomarkers of inflammation and tissue regeneration in CSF than OND suggesting a defective intrinsic immune response playing a role at the beginning of the disease
Beschreibung:Date Completed 28.08.2017
Date Revised 06.02.2018
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2017.05.019